Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the blood and bone marrow. CLL Cytogenetics 3 is an advanced diagnostic panel that combines karyotyping with Fluorescence In Situ Hybridization (FISH) to detect chromosomal abnormalities that are often associated with CLL. These chromosomal abnormalities include deletion in chromosome 17p (del17p), deletion in chromosome 11q (del11q) involving the ATM gene, Trisomy 12, and deletion in chromosome 13q (del13q). The identification of these chromosomal abnormalities is crucial for diagnosis, risk stratification, and management of CLL.
Chronic Lymphocytic Leukemia typically involves a slow build-up of abnormal B lymphocytes in the bone marrow, which can eventually spread to other parts of the body. As CLL progresses, it can lead to a decrease in the production of healthy white blood cells, red blood cells, and platelets. This can result in a weakened immune system, anemia, and increased risk of bleeding. Identifying chromosomal abnormalities in CLL patients can provide important information on how aggressive the leukemia might be and what treatments might be most effective.
Test NameCLL Cytogenetics 3 (Karyotyping, FISH for del17p, del 11q (ATM deletion), Trisomy 12 & del13q)
Sample TypeBlood/bone marrow
Preparations RequiredNo fasting is required. It is advisable to inform your doctor about any medications you are taking.
Report Time12 Days for Karyotype & 5 Days for FISH
What is Chronic Lymphocytic Leukemia (CLL)?
Chronic Lymphocytic Leukemia is a type of cancer that starts from cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer cells spread through the blood to other parts of the body, including other organs and lymph nodes.
Why is the CLL Cytogenetics 3 panel important?
This panel is important for detecting chromosomal abnormalities in CLL. It helps in the diagnosis of CLL and provides valuable information for risk assessment and treatment planning.
Home Sample Collection Process
1
Book your convenient slot
2
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
4
Download Reports
Frequently Asked Questions
This panel provides information on the presence of specific chromosomal abnormalities including del17p, del11q (ATM deletion), Trisomy 12, and del13q. These abnormalities have been associated with different responses to therapy and varied prognoses.
Normal values would show no chromosomal abnormalities. The presence of del17p, del11q, Trisomy 12, or del13q is indicative of CLL.
The test is performed on a blood sample which is examined in the laboratory for chromosomal abnormalities using karyotyping and FISH techniques.
The results provide information that helps your doctor determine the aggressiveness of your CLL and select the most appropriate treatment options. Certain chromosomal abnormalities are associated with resistance to certain therapies and knowing this information can guide treatment decisions.
If the test results are abnormal, consulting a hematologist or oncologist who specializes in blood cancers is advisable.
Del17p is a deletion of the short arm of chromosome 17. It is associated with poor prognosis in CLL and resistance to standard chemotherapy regimens.
Del11q is a deletion of a part of chromosome 11, which includes the ATM gene. This is associated with more aggressive CLL and indicates a high risk of disease progression.
Trisomy 12 means there is an extra copy of chromosome 12. It is one of the common chromosomal abnormalities in CLL and is associated with variable prognosis.
Del13q is a deletion of the long arm of chromosome 13. It is the most common chromosomal abnormality in CLL and is generally associated with a more favorable prognosis.
Karyotyping is a laboratory technique that allows for the visualization of an individual’s chromosomes. It is used to detect structural abnormalities in chromosomes.
No, these chromosomal abnormalities are genetic and are not affected by lifestyle or environmental factors.
This test is generally done at diagnosis to help with risk stratification. It might be repeated if there is a change in disease behavior or before initiating therapy.
There is no specific preparation required for the test.
Detecting and understanding the chromosomal abnormalities in Chronic Lymphocytic Leukemia is critical in the management of the disease. The CLL Cytogenetics 3 panel provides detailed insights that can guide a personalized treatment plan. In coordination with your doctor, this information can be instrumental in monitoring the disease and making informed decisions regarding your health. Regular check-ups and following the treatment plan laid out by your doctor are vital in managing CLL effectively.
CLL-cytogenetics 3 (Karyotyping , FISH for del17p , del 11q (ATM deletion) , trisomy 12 & del13q)
Login / Signup
